{"id":"avxs-101","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"5%","effect":"Fever"},{"rate":"5%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AVXS-101 is a gene therapy that uses a viral vector to deliver a copy of the SMN1 gene to motor neurons, aiming to increase production of the survival motor neuron protein and slow disease progression.","oneSentence":"Gene therapy for spinal muscular atrophy","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:57:27.295Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Spinal muscular atrophy"}]},"trialDetails":[{"nctId":"NCT03837184","phase":"PHASE3","title":"Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies","status":"COMPLETED","sponsor":"Novartis Gene Therapies","startDate":"2019-05-31","conditions":"Spinal Muscular Atrophy Type I","enrollment":2},{"nctId":"NCT03306277","phase":"PHASE3","title":"Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1","status":"COMPLETED","sponsor":"Novartis Gene Therapies","startDate":"2017-10-24","conditions":"SMA - Spinal Muscular Atrophy, Gene Therapy","enrollment":22},{"nctId":"NCT03505099","phase":"PHASE3","title":"Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2","status":"COMPLETED","sponsor":"Novartis Gene Therapies","startDate":"2018-04-02","conditions":"Spinal Muscular Atrophy","enrollment":30},{"nctId":"NCT03461289","phase":"PHASE3","title":"Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1","status":"COMPLETED","sponsor":"Novartis Gene Therapies","startDate":"2018-08-16","conditions":"SMA","enrollment":33},{"nctId":"NCT03381729","phase":"PHASE1","title":"Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy","status":"TERMINATED","sponsor":"Novartis Gene Therapies","startDate":"2017-12-14","conditions":"Spinal Muscular Atrophy","enrollment":32},{"nctId":"NCT05335876","phase":"PHASE3","title":"Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-12-19","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":175},{"nctId":"NCT05386680","phase":"PHASE3","title":"Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-01-12","conditions":"Spinal Muscular Atrophy","enrollment":27},{"nctId":"NCT05089656","phase":"PHASE3","title":"Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-02-01","conditions":"Type 2 Spinal Muscular Atrophy","enrollment":126},{"nctId":"NCT06532474","phase":"","title":"Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-10-29","conditions":"Spinal Muscular Atrophy","enrollment":24},{"nctId":"NCT05575011","phase":"PHASE1","title":"A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2022-10-10","conditions":"Healthy Volunteer, Muscular Atrophy, Spinal","enrollment":62},{"nctId":"NCT03421977","phase":"","title":"Long-Term Follow-up Study for Patients From AVXS-101-CL-101","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Gene Therapies","startDate":"2017-09-21","conditions":"Spinal Muscular Atrophy 1","enrollment":13},{"nctId":"NCT04042025","phase":"PHASE3","title":"Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Gene Therapies","startDate":"2020-02-10","conditions":"Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III","enrollment":85},{"nctId":"NCT04174157","phase":"","title":"Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-09-25","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":700},{"nctId":"NCT06019637","phase":"","title":"A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-22","conditions":"Spinal Muscular Atrophies","enrollment":50},{"nctId":"NCT04851873","phase":"PHASE3","title":"Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-08","conditions":"Spinal Muscular Atrophy","enrollment":24},{"nctId":"NCT05073133","phase":"PHASE4","title":"Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-04","conditions":"Muscular Atrophy, Spinal","enrollment":16},{"nctId":"NCT02122952","phase":"PHASE1","title":"Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1","status":"COMPLETED","sponsor":"Novartis Gene Therapies","startDate":"2014-05-05","conditions":"Spinal Muscular Atrophy 1","enrollment":15},{"nctId":"NCT03955679","phase":"","title":"AveXis Managed Access Program Cohort for Access to AVXS-101","status":"APPROVED_FOR_MARKETING","sponsor":"United BioSource, LLC","startDate":"","conditions":"Spinal Muscular Atrophy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zolgensma"],"phase":"phase_1","status":"active","brandName":"AVXS-101","genericName":"AVXS-101","companyName":"Novartis Gene Therapies","companyId":"novartis-gene-therapies","modality":"Biologic","firstApprovalDate":"","aiSummary":"Gene therapy for spinal muscular atrophy Used for Spinal muscular atrophy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}